{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:07:16Z","timestamp":1790719636205,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T00:00:00Z","timestamp":1346976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s40261-012-0004-6","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T23:10:32Z","timestamp":1355958632000},"page":"723-727","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of Bioequivalence Between Clozapine Suspension and Tablet Formulations"],"prefix":"10.1007","volume":"32","author":[{"given":"Paul","family":"Glue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Menkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelyn","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,7]]},"reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","volume":"25","author":"TR Barnes","year":"2011","unstructured":"Barnes TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:567\u2013620.","journal-title":"J Psychopharmacol"},{"key":"4_CR2","unstructured":"FDA. Guidance for industry: clozapine tablets in vivo bioequivalence and in vitro dissolution testing. 2005."},{"key":"4_CR3","unstructured":"FDA. Guidance for industry: clozapine tablets in vivo bioequivalence and in vitro dissolution testing. 1996."},{"key":"4_CR4","unstructured":"FDA. Guidance for industry: food effect bioavailability and fed bioequivalence studies. 2002."},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00044011-200828040-00004","volume":"28","author":"G Golden","year":"2008","unstructured":"Golden G, Honigfeld G. Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia. Clin Drug Investig. 2008;28:231\u20139.","journal-title":"Clin Drug Investig"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/BF01061471","volume":"20","author":"D Hauschke","year":"1992","unstructured":"Hauschke D, Steinijans VW, Diletti E, Burke M. Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm. 1992;20:557\u201361.","journal-title":"J Pharmacokinet Biopharm"},{"key":"4_CR7","unstructured":"http:\/\/www.mhra.gov.uk\/home\/groups\/l-unit1\/documents\/websiteresources\/con044004.pdf , http:\/\/www.ebs.tga.gov.au and http:\/\/www.medsafe.govt.nz . Accessed 05 February 2012."},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/FTD.0b013e3181f0a1a2","volume":"32","author":"L Couchman","year":"2010","unstructured":"Couchman L, Morgan PE, Spencer EP, Johnston A, Flanagan RJ. Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex). Ther Drug Monit. 2010;32:624\u20137.","journal-title":"Ther Drug Monit"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00044011-200929080-00004","volume":"29","author":"AR Disanto","year":"2009","unstructured":"Disanto AR, Golden G. Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5\u00a0mg: a randomized, open-label, crossover study in healthy male subjects. Clin Drug Investig. 2009;29:539\u201349.","journal-title":"Clin Drug Investig"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0004-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-012-0004-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-012-0004-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:48Z","timestamp":1559503728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-012-0004-6"}},"subtitle":["A Multiple-Dose, Fed and Fasted Study"],"short-title":[],"issued":{"date-parts":[[2012,9,7]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s40261-012-0004-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,7]]}}}